Market research
CAN.AU Cann Group Limited
AU AUD Healthcare
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 8M
- P/E ratio
- 0.25
- Analyst target
- 5
- Beta
- Not available
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- AU000000CAN2
- Market cap
- 8M
- P/E ratio
- 0.25
- Analyst target
- 5
- Beta
- Not available
About
About Cann Group Limited
Cann Group Limited, together with its subsidiaries, engages in the breeding, cultivation, manufacture, and sale of medicinal cannabis in Australia and Europe. Its product portfolio includes the Satipharm delivery system for cannabinoids. The company was founded in 2014 and is based in Mildura, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CAN.AU discussion.
5 years, 5 months ago
Cann Group Limited is currently in a long term downtrend where the price is trading 19.8% below its 200 day moving average.
From a valuation standpoint, the stock is 68.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 81.3.
Cann Group Limited's total revenue rose by 94.6% to $1M since the same quarter in the previous year.
Its net income has dropped by 12.2% to $-9M since the same quarter in the previous year.
Finally, its free cash flow grew by 82.7% to $-6M since the same quarter in the previous year.
Based on the above factors, Cann Group Limited gets an overall score of 3/5.